Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy From Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

Key Takeaways

• GX‑03 achieved 92.6% EASI‑50 at week 4 vs 65.2% vehicle.
• Week‑8 EASI‑90 reached 51.9% for GX‑03 versus 34.8% vehicle.
• No treatment‑related serious adverse events reported in interim cohort.
• Interim data prompting enrollment and endpoint refinements for Phase 2.

Pulse Analysis

Atopic dermatitis affects roughly 10% of U.S. adults, driving demand for fast‑acting, safe topical treatments. Current standards—corticosteroids and newer biologics—balance efficacy with systemic exposure or skin irritation concerns. Turn Therapeutics’ GX‑03, an extended‑release polyhexanide formulation, aims to localize anti‑inflammatory action while minimizing systemic risk, a strategy that aligns with the industry’s shift toward precision skin therapeutics.

The interim findings reveal a striking early response: over 90% of treated participants achieved EASI‑50 within four weeks, a timeline faster than many approved topicals. Moreover, the progression to EASI‑90 by week 8 suggests durable, deep clearance potential. Safety data remain clean, with no serious adverse events or discontinuations, addressing a key barrier that has limited broader adoption of potent topical agents. Compared with existing options, GX‑03 could offer clinicians a rapid‑onset, low‑risk alternative, potentially reshaping treatment algorithms for moderate‑to‑severe disease.

Strategically, Turn Therapeutics is leveraging these results to tighten enrollment criteria and prioritize early inflammatory‑burden endpoints, enhancing statistical power for the trial’s second stage. The company’s planned FDA meeting signals confidence that the data may support accelerated pathways, such as Fast Track or Breakthrough Therapy designation. If subsequent enrollment confirms the interim trends, GX‑03 could capture a sizable share of the $5 billion U.S. atopic dermatitis market, delivering value to patients and investors alike.